GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
“The new preclinical data presented at ASH underscore GlycoMimetics’
commitment to pioneering advances in the field of glycobiology and to
rationally designing innovative drug candidates that address areas of
significant unmet medical need,” said
Details for the two poster presentations on GlycoMimetics’ wholly owned drug candidates follow:
- Publication Number: 4678
TITLE: A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML inPreclinical Models Following Subcutaneous Administration
- Publication Number: 2211
TITLE: A Novel Glycomimetic Compound (GMI-1757) with Dual Functional Antagonism to E-Selectin and Galectin-3 Demonstrates Inhibition of Thrombus Formation in an Inferior Vena Cava Model
About
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of the company’s drug candidates, including the
expected enrollment in and conduct of clinical trials, the presentation
of clinical data, and expiration of issued patents. Actual results may
differ materially from those in these forward-looking statements. For a
further description of the risks associated with these statements, as
well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005097/en/
Source:
Investor Contact:
Shari Annes
Phone: 650-888-0902
Email:
sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email:
jamielacey@presscommpr.com